Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 126.04 USD 0.01%
Market Cap: 7.2B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ascendis Pharma A/S
Cash Equivalents Peer Comparison

Comparables:
GMAB
ZEAL
B
BAVA
F
FLUO
BIOPOR

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Cash Equivalents
€258.7m
CAGR 3-Years
-12%
CAGR 5-Years
-18%
CAGR 10-Years
36%
Genmab A/S
CSE:GMAB
Cash Equivalents
kr4.3B
CAGR 3-Years
-23%
CAGR 5-Years
49%
CAGR 10-Years
27%
Zealand Pharma A/S
CSE:ZEAL
Cash Equivalents
kr511m
CAGR 3-Years
-12%
CAGR 5-Years
-16%
CAGR 10-Years
5%
B
Bavarian Nordic A/S
CSE:BAVA
Cash Equivalents
kr816.4m
CAGR 3-Years
64%
CAGR 5-Years
48%
CAGR 10-Years
22%
F
Fluoguide AS
STO:FLUO
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Cash Equivalents
kr103.9m
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
12%

See Also

What is Ascendis Pharma A/S's Cash Equivalents?
Cash Equivalents
258.7m EUR

Based on the financial report for Jun 30, 2024, Ascendis Pharma A/S's Cash Equivalents amounts to 258.7m EUR.

What is Ascendis Pharma A/S's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
36%

Over the last year, the Cash Equivalents growth was -34%. The average annual Cash Equivalents growth rates for Ascendis Pharma A/S have been -12% over the past three years , -18% over the past five years , and 36% over the past ten years .

Back to Top